secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2026-09-30T12:00:24+00:00
Accession:  0001837607-26-000064
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

AEON Biopharma FDA Type 2b minutes support ABP-450 biosimilar path; milestone warrants to expire Nov 16, 2026
--------------------------------------------------------------------------------

- FDA agreed in principle with two-stage CMAP pharmacodynamic study design in extensor digitorum brevis muscle; AEON plans an IND in Q4 2026 and study start in Q1 2027.
- FDA said Daewoong's prior comparative studies in blepharospasm, upper limb spasticity, glabellar lines and lateral canthal lines may be submitted as supportive evidence, subject to bridging.
- AEON does not intend to start a standalone comparative efficacy study now; it will weigh its analytical, PD and human evidence and return to FDA in 2027 with an integrated package.
- Two-Year Milestone Warrants expire Nov 16, 2026 after AEON determined the Type 2b minutes do not preclude advancement toward a 351(k) BLA, triggering the acceleration clause.
- CEO Rob Bancroft cited a potentially more efficient development program; FDA invited analyses supporting the earlier Phase 2 chronic migraine study for the BLA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000064/0001837607-26-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000064/aeon-20260930x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-26-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer